Condition
Esophageal Squamous Carcinoma
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Unknown3
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07490002Phase 2Not Yet RecruitingPrimary
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
NCT06055153Phase 1UnknownPrimary
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC
NCT05164848Phase 1UnknownPrimary
JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy
NCT01752205Phase 3UnknownPrimary
Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma
Showing all 4 trials